This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
I have read with interest the reply of Dr. Beecham in the Questions and Answers section of The Journal (178:95 [Oct. 7] 1961) regarding the side effects of norethynodrel with ethynylestradiol 3-methyl ether (Enovid) used as a contraceptive. I think that 2 important points were made in regard to stromal hyperplasia and increased growth of uterine fibroids with norethynodrel with ethynylestradiol 3-methyl ether.Dr. Beecham quoted the communication of Dockerty, Smith, and Symmonds, published in the Proceedings of the Mayo Clinic in 1959 in which the problem of stromal hyperplasia was first mentioned. Dockerty has subsequently stated that any qualified pathologist should be able to interpret the unusual endometrial changes induced by these newer agents. It is believed that a number of general pathologists "over-diagnosed" the endometrial changes and that no valid correlation has been shown with sarcoma. Furthermore, no evidence is available to indicate that
Kistner RW. Contraceptive Tablets. JAMA. 1962;179(7):583. doi:10.1001/jama.1962.03050070105023
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: